Burning Rock Biotech Ltd ADR (BNR)

NASD · Healthcare · Diagnostics & Research · China

Burning Rock Biotech Ltd ADR is a micro cap company (market value under $300 million) in the Diagnostics & Research industry.

Intrinsic value, DCF valuation, financial health and value investing analysis for the Burning Rock Biotech Ltd ADR stock.

Our verdict on BNR

Overvalued: intrinsic value $7.37 per share, market price $10.90, margin of safety -47.9% (as of 2026-10-30).

Its liquidation floor, current assets minus every liability, values the shares at $7.37; the price of $10.90 is 48% above that value.

Browse

• Stocks in China
• Healthcare stocks in China

Peers in Diagnostics & Research

• Thermo Fisher Scientific Inc (TMO)
• Danaher Corp (DHR)
• Natera Inc (NTRA)
• Agilent Technologies Inc (A)
• Waters Corp (WAT)
• IQVIA Holdings Inc (IQV)
• Idexx Laboratories Inc (IDXX)
• Illumina Inc (ILMN)

All 44 Diagnostics & Research stocks

Cheaper than BNR in Diagnostics & Research

• Biodesix Inc (BDSX): fairly valued, 2% margin of safety
• Quest Diagnostics Inc (DGX): slightly overvalued, -9% margin of safety
• GeneDx Holdings Corp (WGS): slightly overvalued, -11% margin of safety
• Exagen Inc (XGN): slightly overvalued, -20% margin of safety
• Fulgent Genetics Inc (FLGT): overvalued, -28% margin of safety
• Medpace Holdings Inc (MEDP): overvalued, -30% margin of safety

1 more in this industry show a wider margin of safety.

Is BNR undervalued or overvalued?

BNR is overvalued (as of the 2026-10-30 close). Its liquidation floor, current assets minus every liability, values the shares at $7.37; the price of $10.90 is 48% above that value.

What is the intrinsic value of BNR?

$7.37 per share (as of the 2026-10-30 close), against a market price of $10.90. That is a margin of safety of -47.9%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.